Young Kwang Chae, Professor and Co-Director of Developmental Therapeutics, Lurie Cancer Center at Northwestern University, shared on X:
“PATHFINDER 2 is now published in Nature Medicine.
In >35,000 adults ≥50 years old, a blood-based multi-cancer early detection (MCED) test showed:
- Specificity: 99.64%
- PPV: 60.3%
- Cancer detection rate: 0.54%
- Sensitivity: 39.3% across all cancers
- Sensitivity: 69.8% for 12 cancers responsible for ~⅔ of U.S. cancer deaths
- Cancer signal origin accuracy: 91.3%
- 53% of newly detected cancers were stage I–II
Adding MCED to standard screening detected 6.5× more cancers.
The critical question remains: Will earlier detection translate into lower cancer mortality?
That will require randomized trials and longer follow-up.”
Title: Performance and safety of a multi-cancer early detection test: the PATHFINDER 2 study
Authors: Nima Nabavizadeh, Charles McDonnell, Dax Kurbegov, Marc Matrana, Shirish Gadgeel, Raymond H. Kim, Gretchen Stipec, Kevin C. Oeffinger, Michael J. Demeure, James W. Lillard Jr., Rebecca Kaltman, Jennifer Tran, Alan Roth, SamiTahhan, AndrewPoklepovic, Donald Richards, Margarita Lopatin, Celine Marquez, Margaret McCusker, Karthik V. Giridhar
Read the full article.
Find out more about Multi-Cancer Early Detection on OncoDaily.
